Drug Development Case Studies

Latest Headlines

Xcelience and IriSys business alliance agreement strengthens regional access to CMC/Regulatory expertise

More...

Xcelience Adds Piccola B10 Minipress for GMP Tablet Formulation Development in Experimental Area

More...

Xcelience and Penn Pharma Form a Joint Venture to Provide API Into Capsule Services in Europe and Asia Pacific Markets

More...

Featured Publication
Recent Options for Phase 1 Formulation Development and ClinicalTrial Material Supply. By: Balaji V. Kadri - Featured in the August 2008 Issue of Pharmaceutical Technology

Library

Case Study 0
Publications

Case Study 1
Xcelodose 600 Case Study, Featured in the March 2007 Issue of Tablets & Capsules

Case Study 2
Formulation of an Insoluble Compound with Poor Bioavailability

Case Study 3
Re-formulation and Process Improvement of a Labor Intensive and Expensive Manufacturing Process

Case Study 4
Formulation of an Unstable and Insoluble Compound

Case Study 5
Clinical Proof of Concept Study with an Accelerated Time Frame

Case Study 6
Analytical Method Development for a Low Dose, Poorly Extractable Drug in a Semi-Solid

Case Study 7
Formulation of Low Density and Unstable Drug for Controlled Release Delivery

Case Study 8
Formulation of a Very Poorly Soluble Drug for Parenteral Administration

Case Study 9
Replacement of a Proprietary Controlled Release Technology

Presentations

Accelerated Flexible-Dose Trial Supplies for Early-Stage Clinical Studies

Effects of Powder Characteristics and Operating Conditions on Filling 1mg Weights Using an Xcelodoseâ 600 Micro-Dosing System

Rapid, Sensitive, General-Purpose Cleaning-Verification HPLC Methods Using Fused-Coreä Particle (FCP) Columns on Conventional Instrumentation

Publications

Recent Options for Phase 1 Formulation Development and Clinical Trial Material Supply. By: Balaji V. Kadri - Featured in the August 2008 Issue of Pharmaceutical Technology

Case Study 0
Publications

Case Study 1
Xcelodose 600 Case Study, Featured in the March 2007 Issue of Tablets & Capsules

Case Study 2
Formulation of an Insoluble Compound with Poor Bioavailability

Case Study 3
Re-formulation and Process Improvement of a Labor Intensive and Expensive Manufacturing Process

Case Study 4
Formulation of an Unstable and Insoluble Compound

Case Study 5
Clinical Proof of Concept Study with an Accelerated Time Frame

Case Study 6
Analytical Method Development for a Low Dose, Poorly Extractable Drug in a Semi-Solid

Case Study 7
Formulation of Low Density and Unstable Drug for Controlled Release Delivery

Case Study 8
Formulation of a Very Poorly Soluble Drug for Parenteral Administration

Case Study 9
Replacement of a Proprietary Controlled Release Technology

Presentations

Accelerated Flexible-Dose Trial Supplies for Early-Stage Clinical Studies

Effects of Powder Characteristics and Operating Conditions on Filling 1mg Weights Using an Xcelodoseâ 600 Micro-Dosing System

Rapid, Sensitive, General-Purpose Cleaning-Verification HPLC Methods Using Fused-Coreä Particle (FCP) Columns on Conventional Instrumentation

Publications

Recent Options for Phase 1 Formulation Development and Clinical Trial Material Supply. By: Balaji V. Kadri - Featured in the August 2008 Issue of Pharmaceutical Technology

Case Study 0
Publications

Case Study 1
Xcelodose 600 Case Study, Featured in the March 2007 Issue of Tablets & Capsules

Case Study 2
Formulation of an Insoluble Compound with Poor Bioavailability

Case Study 3
Re-formulation and Process Improvement of a Labor Intensive and Expensive Manufacturing Process

Case Study 4
Formulation of an Unstable and Insoluble Compound

Case Study 5
Clinical Proof of Concept Study with an Accelerated Time Frame

Case Study 6
Analytical Method Development for a Low Dose, Poorly Extractable Drug in a Semi-Solid

Case Study 7
Formulation of Low Density and Unstable Drug for Controlled Release Delivery

Case Study 8
Formulation of a Very Poorly Soluble Drug for Parenteral Administration

Case Study 9
Replacement of a Proprietary Controlled Release Technology

Presentations

Accelerated Flexible-Dose Trial Supplies for Early-Stage Clinical Studies

Effects of Powder Characteristics and Operating Conditions on Filling 1mg Weights Using an Xcelodoseâ 600 Micro-Dosing System

Rapid, Sensitive, General-Purpose Cleaning-Verification HPLC Methods Using Fused-Coreä Particle (FCP) Columns on Conventional Instrumentation

Publications

Recent Options for Phase 1 Formulation Development and Clinical Trial Material Supply. By: Balaji V. Kadri - Featured in the August 2008 Issue of Pharmaceutical Technology

Case Study 0
Publications

Case Study 1
Xcelodose 600 Case Study, Featured in the March 2007 Issue of Tablets & Capsules

Case Study 2
Formulation of an Insoluble Compound with Poor Bioavailability

Case Study 3
Re-formulation and Process Improvement of a Labor Intensive and Expensive Manufacturing Process

Case Study 4
Formulation of an Unstable and Insoluble Compound

Case Study 5
Clinical Proof of Concept Study with an Accelerated Time Frame

Case Study 6
Analytical Method Development for a Low Dose, Poorly Extractable Drug in a Semi-Solid

Case Study 7
Formulation of Low Density and Unstable Drug for Controlled Release Delivery

Case Study 8
Formulation of a Very Poorly Soluble Drug for Parenteral Administration

Case Study 9
Replacement of a Proprietary Controlled Release Technology

Presentations

Accelerated Flexible-Dose Trial Supplies for Early-Stage Clinical Studies

Effects of Powder Characteristics and Operating Conditions on Filling 1mg Weights Using an Xcelodoseâ 600 Micro-Dosing System

Rapid, Sensitive, General-Purpose Cleaning-Verification HPLC Methods Using Fused-Coreä Particle (FCP) Columns on Conventional Instrumentation

Publications

Recent Options for Phase 1 Formulation Development and Clinical Trial Material Supply. By: Balaji V. Kadri - Featured in the August 2008 Issue of Pharmaceutical Technology

Case Study 0
Publications

Case Study 1
Xcelodose 600 Case Study, Featured in the March 2007 Issue of Tablets & Capsules

Case Study 2
Formulation of an Insoluble Compound with Poor Bioavailability

Case Study 3
Re-formulation and Process Improvement of a Labor Intensive and Expensive Manufacturing Process

Case Study 4
Formulation of an Unstable and Insoluble Compound

Case Study 5
Clinical Proof of Concept Study with an Accelerated Time Frame

Case Study 6
Analytical Method Development for a Low Dose, Poorly Extractable Drug in a Semi-Solid

Case Study 7
Formulation of Low Density and Unstable Drug for Controlled Release Delivery

Case Study 8
Formulation of a Very Poorly Soluble Drug for Parenteral Administration

Case Study 9
Replacement of a Proprietary Controlled Release Technology

Presentations

Accelerated Flexible-Dose Trial Supplies for Early-Stage Clinical Studies

Effects of Powder Characteristics and Operating Conditions on Filling 1mg Weights Using an Xcelodoseâ 600 Micro-Dosing System

Rapid, Sensitive, General-Purpose Cleaning-Verification HPLC Methods Using Fused-Coreä Particle (FCP) Columns on Conventional Instrumentation

Publications

Recent Options for Phase 1 Formulation Development and Clinical Trial Material Supply. By: Balaji V. Kadri - Featured in the August 2008 Issue of Pharmaceutical Technology

Drug Development Services | Pharmaceutical Pre-Formulation Development | Pharmaceutical Formulation Development
Drug Development Analytical Method | Xcelodose Drug Manufacturing | Drug Delivery Expert Consulting | BOOKMARK US

Copyright © 2010 Xcelience All rights reserved.
Website Designed by GI & Hi-Tech - Tampa, FL